BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced promising new clinical data on SAINT® therapy at the 2024 NYC Neuromodulation Conference, Aug 1-3. The research will be presented in two posters demonstrating the long-lasting benefits of SAINT treatment and its potential for personalized continuation therapy in people with treatment-resistant depression (TRD).
“We’re excited to share these new findings at this year’s NYC Neuromodulation Conference, which further validate the transformative potential of the SAINT therapy in providing durable relief for people with debilitating intractable depression and offering a pathway for personalized continuation treatment to maintain remission,” said Brandon Bentzley, M.D., Ph.D., co-founder and CSO, Magnus Medical. “The potential life-saving impact is truly inspiring.”
“Furthermore, building on the strength of this compelling research, we are rapidly expanding access to the SAINT neuromodulation system, delivering it to hospitals and private clinics across the country,” continued Dr. Bentzley.
Research Highlights:
- Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT, commercially known as SAINT) in treatment-resistant depression: assessment of sustained remission and response following index treatment
This study, conducted by researchers at Stanford University, provides the first longer-term data on the durability of SAINT's antidepressant effect in patients with TRD. The results indicate that a single five-day course of treatment offers substantial and durable clinical benefits, with patients remaining in remission for an average of 11 weeks and in a state of response for an average of 15 weeks.
- An Open-Label Pilot Trial to Assess the Feasibility of Using the Magnus Neuromodulation System with Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) as a Personalized Continuation Therapy for Depression
This study, led by Magnus Medical with Acacia Clinics, investigated the use of SAINT as a personalized continuation therapy for people with TRD who initially responded to an acute course of SAINT treatment. The results demonstrate that this approach is safe, well-tolerated, and highly effective in maintaining remission from depression for 12 months.
Treatment with SAINT changes a person’s brain circuitry to treat major depression more effectively by modifying activity in brain networks that are related to depression. Granted Breakthrough Device Designation and 510(k) clearance by the U.S. Food & Drug Administration (FDA), SAINT therapy has led to dramatic improvements in people’s symptoms of severe depression in a clinical setting.
SAINT therapy works by leveraging structural and functional magnetic resonance imaging (MRI) scans to inform a proprietary algorithm that pinpoints the optimal anatomical target for precise neurostimulation in individuals with major depression. The innovative treatment is performed on an accelerated, five-day timeline, ensuring that stimulation targeting is meticulously customized to each person’s unique brain connectivity.
About Magnus
Magnus Medical, Inc., is a privately held therapeutic neuromodulation company driven to transform lives by restoring mental health. Co-founded in 2020, the company’s first product is the SAINT neuromodulation system, which provides a new form of individualized neurostimulation for treatment-resistant depression indicated for adults who have failed to achieve satisfactory improvement from prior antidepressant medications. For more information, visit https://www.magnusmed.com.
